scholarly journals pH of Drinking Water Influences the Composition of Gut Microbiome and Type 1 Diabetes Incidence

Diabetes ◽  
2013 ◽  
Vol 63 (2) ◽  
pp. 632-644 ◽  
Author(s):  
M. H. Sofi ◽  
R. Gudi ◽  
S. Karumuthil-Melethil ◽  
N. Perez ◽  
B. M. Johnson ◽  
...  
Diabetes ◽  
2015 ◽  
Vol 64 (8) ◽  
pp. e20-e21 ◽  
Author(s):  
M. Hanief Sofi ◽  
Benjamin M. Johnson ◽  
Radhika Gudi ◽  
Kyle J. Wolf ◽  
Robin G. Lorenz ◽  
...  

Diabetes ◽  
2018 ◽  
Vol 67 (Supplement 1) ◽  
pp. 209-LB ◽  
Author(s):  
JORDAN RUSSELL ◽  
LUIZ ROESCH ◽  
MARK A. ATKINSON ◽  
DESMOND SCHATZ ◽  
ERIC W. TRIPLETT ◽  
...  

Diabetologia ◽  
2021 ◽  
Author(s):  
Nicholas J. Thomas ◽  
John M. Dennis ◽  
Seth A. Sharp ◽  
Akaal Kaur ◽  
Shivani Misra ◽  
...  

Abstract Aims/hypothesis Among white European children developing type 1 diabetes, the otherwise common HLA haplotype DR15-DQ6 is rare, and highly protective. Adult-onset type 1 diabetes is now known to represent more overall cases than childhood onset, but it is not known whether DR15-DQ6 is protective in older-adult-onset type 1 diabetes. We sought to quantify DR15-DQ6 protection against type 1 diabetes as age of onset increased. Methods In two independent cohorts we assessed the proportion of type 1 diabetes cases presenting through the first 50 years of life with DR15-DQ6, compared with population controls. In the After Diabetes Diagnosis Research Support System-2 (ADDRESS-2) cohort (n = 1458) clinician-diagnosed type 1 diabetes was confirmed by positivity for one or more islet-specific autoantibodies. In UK Biobank (n = 2502), we estimated type 1 diabetes incidence rates relative to baseline HLA risk for each HLA group using Poisson regression. Analyses were restricted to white Europeans and were performed in three groups according to age at type 1 diabetes onset: 0–18 years, 19–30 years and 31–50 years. Results DR15-DQ6 was protective against type 1 diabetes through to age 50 years (OR < 1 for each age group, all p < 0.001). The following ORs for type 1 diabetes, relative to a neutral HLA genotype, were observed in ADDRESS-2: age 5–18 years OR 0.16 (95% CI 0.08, 0.31); age 19–30 years OR 0.10 (0.04, 0.23); and age 31–50 years OR 0.37 (0.21, 0.68). DR15-DQ6 also remained highly protective at all ages in UK Biobank. Without DR15-DQ6, the presence of major type 1 diabetes high-risk haplotype (either DR3-DQ2 or DR4-DQ8) was associated with increased risk of type 1 diabetes. Conclusions/interpretation HLA DR15-DQ6 confers dominant protection from type 1 diabetes across the first five decades of life. Graphical abstract


2006 ◽  
Vol 1079 (1) ◽  
pp. 365-368 ◽  
Author(s):  
T. SHIGIHARA ◽  
Y. OKUBO ◽  
Y. KANAZAWA ◽  
Y. OIKAWA ◽  
A. SHIMADA

Diabetologia ◽  
2019 ◽  
Vol 62 (12) ◽  
pp. 2252-2261 ◽  
Author(s):  
Johan Verhagen ◽  
Norkhairin Yusuf ◽  
Emma L. Smith ◽  
Emily M. Whettlock ◽  
Kerina Naran ◽  
...  

Abstract Aims/hypothesis The molecular basis for the pathological impact of specific HLA molecules on autoimmune diseases such as type 1 diabetes remains unclear. Recent natural history studies in children have indicated a link between specific HLA genotypes and the first antigenic target against which immune responses develop. We set out to examine this link in vivo by exploring the diabetogenicity of islet antigens on the background of a common diabetes-associated HLA haplotype. Methods We generated a novel HLA-transgenic mouse model that expresses high-risk genes for type 1 diabetes (DRB1*03:01-DQA1*05:01-DQB1*02:01) as well as human CD80 under the rat insulin promoter and human CD4, on a C57BL/6 background. Adjuvanted antigen priming was used to reveal the diabetogenicity of candidate antigens and peptides. Results HLA-DR3-DQ2+huCD4+IA/IE−/−RIP.B7.1+ mice spontaneously developed autoimmune diabetes (incidence 46% by 35 weeks of age), accompanied by numerous hallmarks of human type 1 diabetes (autoantibodies against GAD65 and proinsulin; pancreatic islet infiltration by CD4+, CD8+ B220+, CD11b+ and CD11c+ immune cells). Disease was markedly accelerated and had deeper penetrance after adjuvanted antigen priming with proinsulin (mean onset 11 weeks and incidence 100% by 20 weeks post challenge). Moreover, the diabetogenic effect of proinsulin located to the 15-residue B29-C11 region. Conclusions/interpretation Our study identifies a proinsulin-derived peptide region that is highly diabetogenic on the HLA-DR3-DQ2 background using an in vivo model. This approach and the peptide region identified may have wider implications for future studies of human type 1 diabetes.


2021 ◽  
Author(s):  
Monica Westley ◽  
Tiffany Richardson ◽  
Suhana Bedi ◽  
Baofeng Jia ◽  
Fiona S.L. Brinkman ◽  
...  

Abstract    A variety of islet autoantibodies (AAbs) can predict and possibly dictate eventual type 1 diabetes (T1D) diagnosis. Upwards of 75% of those with T1D are positive for AAbs against glutamic acid decarboxylase (GAD65), a producer of gamma-aminobutyric acid (GABA) in human pancreatic beta cells. Interestingly, bacterial populations within the human gut also express GAD65 and produce GABA. Evidence suggests that dysbiosis of the microbiome may correlate with T1D pathogenesis and physiology. Therefore, autoimmune linkages between the gut microbiome and islets susceptible to autoimmune attack need to be further elucidated. Utilizing silico analyses, we show here that 25 GAD sequences from different human gut bacterial sources show sequence and motif similarities to human beta cell GAD65. Our motif analyses determined that a majority of gut GAD sequences contain the pyroxical dependent decarboxylase domain of human GAD65 which is important for its enzymatic activity. Additionally, we showed overlap with known human GAD65 T-cell receptor epitopes which may implicate the immune destruction of beta cells. Thus, we propose a physiological hypothesis in which changes in the gut microbiome in those with T1D result in a release of bacterial GAD, thus causing miseducation of the host immune system. Due to the notable similarities, we found between humans and bacterial GAD, these deputized immune cells may then go on to target human beta cells leading to the development of T1D.


2014 ◽  
Vol 99 (11) ◽  
pp. E2353-E2356 ◽  
Author(s):  
Marjaana Mäkinen ◽  
Ville Simell ◽  
Juha Mykkänen ◽  
Jorma Ilonen ◽  
Riitta Veijola ◽  
...  

Diabetes Care ◽  
2002 ◽  
Vol 25 (9) ◽  
pp. 1534-1538 ◽  
Author(s):  
L. C. Stene ◽  
D. Hongve ◽  
P. Magnus ◽  
K. S. Ronningen ◽  
G. Joner

2016 ◽  
Vol 20 (1) ◽  
pp. 121 ◽  
Author(s):  
Aleksandar D. Kostic ◽  
Dirk Gevers ◽  
Heli Siljander ◽  
Tommi Vatanen ◽  
Tuulia Hyötyläinen ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document